Mustang Bio (MBIO) Strong Safety and Efficacy CD20 Data Update Derisks Phase 1/2- BTIG
Tweet Send to a Friend
BTIG analyst Justin Zelin reiterated a Buy rating and $11.00 price target on Mustang Bio (NASDAQ: MBIO) after MB-106 follow-up ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
